Malignant Ascites

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2025-09-24
EMA Authorised: Korjuny (catumaxomab) — Atnahs Pharma Netherlands B.V.
The European Medicines Agency authorised Korjuny (catumaxomab) by Atnahs Pharma Netherlands B.V. for the treatment of malignant ascites.